BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis Sells 30,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 30,000 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $408,600. This trade represents a 71.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

BridgeBio Pharma Stock Performance

BBIO opened at $34.07 on Friday. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The company’s 50 day simple moving average is $34.13 and its 200 day simple moving average is $29.46. The stock has a market capitalization of $6.48 billion, a PE ratio of -11.95 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. As a group, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently added to or reduced their stakes in BBIO. California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma by 6.8% in the 4th quarter. California State Teachers Retirement System now owns 115,655 shares of the company’s stock valued at $3,174,000 after purchasing an additional 7,388 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in BridgeBio Pharma during the fourth quarter valued at approximately $5,076,000. Mackenzie Financial Corp grew its stake in BridgeBio Pharma by 6.6% during the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after buying an additional 592 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of BridgeBio Pharma in the fourth quarter worth $109,000. Finally, Frazier Life Sciences Management L.P. increased its position in shares of BridgeBio Pharma by 1.1% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after acquiring an additional 40,000 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

BBIO has been the subject of several recent analyst reports. Scotiabank raised their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a research report on Monday. They set a “buy” rating and a $50.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 24th. Finally, Evercore ISI upped their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $52.64.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.